We are live on ! Find out more
BRM

Boston Research & Management Portfolio holdings

AUM $421M
1-Year Est. Return 16.18%
This Fund
S&P 500
This Quarter Est. Return
-4.06%
1 Year Est. Return
+16.18%
3 Year Est. Return
+48.21%
5 Year Est. Return
+65.09%
10 Year Est. Return
+242.1%
AUM
$338M
AUM Growth
-$14.8M
Cap. Flow
+$1.69M
Cap. Flow %
0.5%
Top 10 Hldgs %
27.46%
Holding
115
New
2
Increased
44
Reduced
22
Closed
1

Top Buys

Rank Stock Value
1
FTRE icon
Fortrea Holdings
FTRE
+$662K
2
XOM icon
ExxonMobil
XOM
+$348K
3
DIS icon
Walt Disney
DIS
+$313K
4
VZ icon
Verizon
VZ
+$284K
5
ODFL icon
Old Dominion Freight Line
ODFL
+$198K

Top Sells

Rank Stock Value
1
LH icon
Labcorp
LH
+$656K
2
MSFT icon
Microsoft
MSFT
+$496K
3
CLX icon
Clorox
CLX
+$218K
4
AAPL icon
Apple
AAPL
+$128K
5
IVV icon
iShares Core S&P 500 ETF
IVV
+$86.3K

Sector Composition

Rank Sector Weight
1 Technology 14.23%
2 Healthcare 13.58%
3 Consumer Staples 11.22%
4 Industrials 10.28%
5 Consumer Discretionary 8.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
QRVO icon
51
Qorvo
QRVO
$8.43B
$2.89M 0.85%
30,271
+55
+0.2% +$5.62K
HD icon
52
Home Depot
HD
$348B
$2.81M 0.83%
9,294
-131
-1% -$42.1K
USB icon
53
US Bancorp
USB
$101B
$2.67M 0.79%
80,699
+5,171
+7% +$188K
CTAS icon
54
Cintas
CTAS
$81.5B
$2.66M 0.79%
22,120
VTI icon
55
Vanguard Morningstar Total Stock Market ETF
VTI
$684B
$2.63M 0.78%
12,380
IJH icon
56
iShares Core S&P Mid-Cap ETF
IJH
$126B
$2.5M 0.74%
50,205
+335
+0.7% +$17.6K
LLY icon
57
Eli Lilly
LLY
$991B
$2.38M 0.7%
4,433
VB icon
58
Vanguard Morningstar Small-Cap ETF
VB
$82.3B
$2.11M 0.62%
11,185
-60
-0.5% -$12K
HYG icon
59
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
$16.6B
$2.08M 0.61%
28,156
+1,289
+5% +$96.2K
IBB icon
60
iShares Biotechnology ETF
IBB
$9.36B
$1.99M 0.59%
16,266
-20
-0.1% -$2.54K
BBH icon
61
VanEck Biotech ETF
BBH
$403M
$1.98M 0.59%
12,721
IAU icon
62
iShares Gold Trust
IAU
$63.4B
$1.84M 0.55%
52,753
GOOG icon
63
Alphabet (Google) Class C
GOOG
$4.61T
$1.56M 0.46%
11,820
HYD icon
64
VanEck High Yield Muni ETF
HYD
$4.44B
$1.56M 0.46%
31,766
-1,655
-5% -$83.8K
JNJ icon
65
Johnson & Johnson
JNJ
$612B
$1.51M 0.45%
9,711
-62
-0.6% -$10.2K
CVX icon
66
Chevron
CVX
$380B
$1.49M 0.44%
8,808
SYK icon
67
Stryker
SYK
$129B
$1.19M 0.35%
4,354
VEU icon
68
Vanguard FTSE All-World ex-US ETF
VEU
$68.1B
$1.15M 0.34%
22,118
ORCL icon
69
Oracle
ORCL
$424B
$1.09M 0.32%
10,319
CAT icon
70
Caterpillar
CAT
$409B
$966K 0.29%
3,542
VEA icon
71
Vanguard FTSE Developed Markets ETF
VEA
$234B
$961K 0.28%
21,999
-1,117
-5% -$51.1K
PAYX icon
72
Paychex
PAYX
$42B
$878K 0.26%
7,615
-60
-0.8% -$7.23K
PFE icon
73
Pfizer
PFE
$145B
$797K 0.24%
24,041
VWO icon
74
Vanguard FTSE Emerging Markets ETF
VWO
$123B
$683K 0.2%
17,438
PFF icon
75
iShares Preferred and Income Securities ETF
PFF
$13.3B
$672K 0.2%
22,299
-924
-4% -$28.2K

Similar funds

Boston Research & Management's Q3 2023 Portfolio in Review

As of Q3 2023, Boston Research & Management held 115 positions worth $338M, down 4.2% from $353M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Trading was light in Q3 2023: portfolio turnover was 2.6%. Boston Research & Management opened 2 new positions and exited 1, leaving the 115-position portfolio largely intact.

By sector, the portfolio is most concentrated in Technology at 14% of assets, down from 14% a quarter earlier, followed by Healthcare and Consumer Staples.

  • Boston Research & Management's largest Q3 2023 buy was Fortrea Holdings: 22,375 shares worth $639K.
  • Boston Research & Management added most to ExxonMobil in Q3 2023, an estimated $348K increase.
  • Boston Research & Management's biggest Q3 2023 reduction was Labcorp, cutting an estimated $656K.
  • Boston Research & Management fully exited Clorox in Q3 2023, selling an estimated $218K.
  • Boston Research & Management's ten largest holdings make up 27% of its $338M portfolio in Q3 2023.
  • Boston Research & Management opened 2 new positions and closed 1 in Q3 2023.
  • Boston Research & Management's portfolio value fell 4.2% quarter-over-quarter to $338M.

Based on Boston Research & Management's 13F filing for Q3 2023, filed 13 Nov 2023.